Oppenheimer Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $145
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Oppenheimer analyst Leland Gershell maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $125 to $145.
Oppenheimer analyst Leland Gershell maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $125 to $145.